ArticleDiscover oncology2025
SFRP2 and RPRM as methylation based serum biomarkers for the detection of gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.Cancers · 2026Review
- Maternal Nutrient Restriction Programs Fetal Hepatic DNA Methylation in Ovine Monozygotic Twins.International journal of molecular sciences · 2026Article
- The Double-Edged Sword of Genomic DNA Methylation: Orchestrating Gastric Carcinogenesis and Shaping Precision Oncology.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGastric cancer (GC) has a high mortality rate due to the diagnosis in advanced stages. Aberrant DNA methylation is the earliest event in carcinogenesis and can be noninvasively detected in cell-free DNA (cfDNA) from gastric cancer patients.
methodsA total of 143 serum samples were analyzed, including 33 GC patients, 30 chronic gastritis (ChG) patients, and 80 healthy individuals. Additionally, tissue samples were collected from 30 GC patients (stages I-IV) and 38 ChG patients. Methylation patterns of ten genes were examined in GC cells, as well as in serum and tissue samples from GC, ChG, and control groups using methylation-specific qPCR. Statistical evaluations were conducted on various parameters including Ct differences, categorical variables, sensitivity, and specificity.
resultsAPC, CDH1, RASSF1A, hMLH1, RUNX3, p16, SFRP2, RNF180, PCDH10, and RPRM were all significantly hypermethylated in the tissues of GC patients compared to those with ChG (P < 0.001). SFRP2, RPRM, APC, PCDH10, and RNF180 genes were analyzed in sera of 3 groups. Among them, SFRP2 methylation was detected in 71.87% of GC, 16.6% of ChG and 8.8% of the control group. The methylation frequencies of RPRM were 66.6% in GC, 13.3% in ChG, and 7.5% in the control group. In a dual-gene panel assay combining SFRP2 and RPRM, the sensitivity and specificity for detecting gastric cancer in serum samples were 57.58% and 96.25%, respectively, when comparing the cancer and control groups. The sensitivity was 78.79%, the specificity was 90.00% and AUC was 0.931 for GC and control groups (P < 0.0001). The sensitivity was 78.79%, the specificity was 83.33% and AUC was 0.879 for the discrimination of GC and ChG (P < 0.0001).
conclusionsMethylation of 10 genes were studied and a prototype early diagnosis tool for GC utilizing SFRP2 and RPRM with high sensitivity and specificity was developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.